Compare Aspire Biopharma Holdings, Inc. (ASBP) vs Caris Life Sciences, Inc. (CAI) Stock

Analysts rate Caris Life Sciences, Inc. (CAI) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Caris Life Sciences, Inc. (CAI) delivered a total return of -29.1%, compared to -88.5% for Aspire Biopharma Holdings, Inc. (ASBP). A $10,000 investment in CAI five years ago would be worth approximately $7K today (assuming dividends reinvested). Over 10 years, the gap is even starker: CAI returned -29.1% versus ASBP's -88.5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Caris Life Sciences, Inc. (CAI) is the lower-risk stock at 1.09β versus Aspire Biopharma Holdings, Inc.'s 1.61β — meaning ASBP is approximately 47% more volatile than CAI relative to the S&P 500.

Caris Life Sciences, Inc. (CAI) is the more profitable company, earning -66.2% net margin versus -16352.0% for Aspire Biopharma Holdings, Inc. — meaning it keeps -66.2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CAI leads at 5.6% versus -10314.4% for ASBP. At the gross margin level — before operating expenses — CAI leads at 46.2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Caris Life Sciences, Inc. (CAI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.09)). Aspire Biopharma Holdings, Inc. (ASBP) carries a higher beta of 1.61 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CAI: -29.1%, ASBP: -88.5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.